Medical devices & diagnostics · Neurosurgical navigation
Zeta Surgical
A computer vision system that keeps a brain target locked while the patient moves, so guided procedures can happen outside the operating room. Six FDA clearances since September 2023, one 15 patient study, and a commercial rollout that has just begun.
The catheter that nobody guides
An external ventricular drain is among the most common life saving procedures in neurosurgery, and among the least guided. Someone marks a point on the scalp, drills, and passes a catheter toward a fluid space roughly the width of a finger, working from surface anatomy and practice.
Navigation systems exist and are accurate. They also sit in the operating room, tied to a workflow that wants a rigid head frame, general anesthesia and a full team. So the emergency version, done at a bedside on a patient who is awake and moving, is usually done freehand.
Zeta Surgical was built to take that constraint apart. Its system points a 3D sensor at the patient, matches the live surface to a CT or MRI scan without markers or pins, and redoes the match continuously. The company says tracking runs 20 times a second. If the head shifts, the overlay follows.
In June 2023 a surgeon at Singapore’s National Neuroscience Institute placed a ventricular catheter using it. Co-founder William Gormley, a Harvard neurosurgeon, described the moment in the announcement: “Placing a navigated bedside ventricular catheter in a mobile, non-cranially-pinned patient is truly a landmark accomplishment.”
The problem is deployment, not accuracy
Neuronavigation is a mature category. The gold standard for placement accuracy sits near one millimeter. TSVC, an early investor, set out the gap in a January 2023 write up: legacy navigation, neurosurgical robots and augmented reality all share slow setup, confinement to the operating room, and a need for the patient to be anesthetized.
That leaves a large set of procedures unguided by default. Zeta tells reporters the pool is “the 19.6 million annual neurological interventions currently unsupported by existing navigation systems”, a company figure repeated in trade coverage without an independent check.
Amich put the ambition plainly to a Swiss economic development group in March 2026: “In brain procedures, a few millimeters can matter enormously. Yet precise navigation is practically only available in scarce, expensive operating rooms.”
Two undergraduates and their professor
Jose Maria Amich and Raahil Sha met at Harvard and were writing computer vision code before they graduated in 2018. Amich had already run a social venture with Massachusetts General Hospital making inexpensive pinhole lens glasses for children, and spent half a year in Kenya on a pilot study. Sha took a computer science degree and wrote the registration algorithm the product still runs on.
They brought the work to Gormley, a Harvard Medical School associate professor and Brigham and Women’s Hospital neurosurgeon who had spent decades on image guidance. He became the third co-founder and the chief medical officer.
Being 22 was the objection investors kept returning to. Amich told an interviewer in 2022 that the answer was borrowed seniority: “We created a support network of advisors and senior managers, who can help and guide us during the most important decisions and moments.”
Cadavers, then clearances, then clinics
The evidence built in the right order: a 2020 paper on computer vision registration, a 2021 Journal of Neurosurgery cadaveric study of bedside external ventricular drain placement, a 2022 Operative Neurosurgery cadaveric study of stereotactic robotics with real time tracking, and a 2023 Bioengineering paper, all with Harvard and Singapore collaborators.
In March 2022 the company announced a $5.2 million seed round led by Innospark Ventures, with TSVC, Y Combinator and former Tenet Healthcare chief executive Trevor Fetter. The first FDA clearance landed in September 2023. Five more followed by July 2026.
Commercial traction arrived later and narrower than the clearance count suggests. The first named customer came in May 2026: a HOPE Therapeutics clinic in West Palm Beach, Florida, part of NRx Pharmaceuticals, running navigated transcranial magnetic stimulation for depression. Chief business officer Vincent Lan called it “our transition from research and development into a commercial rollout”. That was four years after the seed round.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| First clearance, K230661 | Zeta Cranial Navigation System, cleared Sep 8, 2023. Traditional 510(k), regulation 882.4560, product code HAW, neurological stereotaxic instrument. | Public record |
| Two special 510(k)s | K233903 cleared Jan 10, 2024 and K242351 cleared Oct 4, 2024, both under HAW, for software changes, uncapped navigation speed, more accessories and hospital IT integration. | Public record |
| TMS navigation, K251927 | Cleared Oct 10, 2025, special 510(k) under 882.4560, primary code SGE with QFF subsequent. FDA classifies it as an extracranial positional system for a TMS system. The company says it is the first TMS navigation device cleared under SGE. | Public record |
| Instruments, K253663 | Cleared May 1, 2026, traditional 510(k) under HAW. Covers the Zeta Stylet and Zeta Bolt for catheter and shunt placement, brain biopsy and trigeminal rhizotomy. | Public record |
| Robotic arm, K261471 | Cleared Jul 9, 2026. FDA lists regulation 882.5805, primary code QFF, classification “Electromechanical Arm For A Transcranial Magnetic Stimulation System”, and names the device the Zeta TMS Navigation System. | Public record |
| How that clearance is described | The company release calls the product the Zeta TMS Robotic System and says it is “classified as a Class II stereotaxic instrument under 21 CFR 882.4560 and product codes SGE and QFF (K261471)”. The FDA record gives 882.5805, not 882.4560, and a different classification name. | Differs from FDA record |
| First-in-human study | 15 patients needing elective and emergency ventriculostomy at Singapore General Hospital and Tan Tock Seng Hospital, led by Dr Min Wei Chen. First patient June 2023, completion announced June 2024, all cannulated in one attempt with no adverse events. | Company-stated |
| That study in the literature | No peer-reviewed publication of the trial and no ClinicalTrials.gov registration found as of Sep 22, 2026. The PubMed-indexed Zeta papers are cadaveric or bench work. | Not found |
| Bedside or operating room | The 2023 release says the trial evaluates the system “for pin-less bedside ventriculostomy procedures”. The company case page says of the same study: “In this first-in-human study, all procedures were performed in the OR”. | Company sources differ |
| Freehand comparison figures | The website contrasts 100% single-pass placement against 81% freehand, 0% revisions against 19%, 0% adverse events against 28% and 100% ideal placement against 32%. The comparators are unsourced and not from a randomised arm. | Company-stated |
| Federal funding | No NIH or NSF award to Zeta Surgical or Z Imaging found. The 18 NSF hits a name search returns all belong to other companies. | Not found |
| Registered trials | NCT07227103, a 400 patient phase 2 and 3 study of NRX-101 with robotic TMS, is sponsored by NeuroRx, Inc., not Zeta, and was listed as not yet recruiting. | Public record |
Read plainly: the regulatory record is real and unusually fast for a company this size. Six clearances in under three years, two in a product code no competitor had used for TMS navigation, is not a paper achievement. The clinical record is thinner. One 15 patient study is the whole human dataset in public view, and its comparison numbers are set against historical freehand rates rather than a control arm.
What to watch
- A peer-reviewed publication of the Singapore trial. It is the one thing that would move the clinical claims from release to record.
- The large-scale pilot with the Big Ten Neurosurgical Consortium, announced in May 2026 for later that year. No launch has been reported.
- Whether the robotic TMS arm cleared in July 2026 ships. The coverage carried no outcome data and no timeline.
- CE mark and the Greater Zurich hub, which Amich described in March 2026 as a 12 to 24 month build.
- A new Form D. The last one reached EDGAR in November 2023.
In their words
“There is this giant disconnect between the precision we have on one hand, and the complete lack of technology and precision we have for the other group of surgeries”
William Gormley, co-founder and chief medical officer, TechCrunch, 2022 · Independent
“We have considered both AR and VR systems, but for the moment, we’re going with the standard screen-based navigation”
Raahil Sha, co-founder and CTO, TechCrunch, 2022 · Independent
“Zeta can be used to navigate cases currently performed freehand, which reduces complications and improves efficacy of treatments”
Jose Amich, co-founder and CEO, to MobiHealthNews, 2024 · Independent
“It has been an enlightening journey watching how the project evolved from the lab to the operating theater. The results of the trial speak for themselves”
Dr Min Wei Chen, National Neuroscience Institute, Singapore, 2024 release · Company release
“We looked for investors who had previous experience with medical devices.”
Jose Amich, Fund Your Way interview, 2022 · Interview
“The frustration is not that there is a lack of demand for better technology. It is that every step between a cleared product and routine clinical use can be slow and fragmented.”
Jose Amich, Greater Zurich Area interview, 2026 · Interview
“This clearance brings operating-room-level navigation and robotic accuracy into a platform that can be rapidly deployed in virtually any clinic”
William Gormley, co-founder, July 2026 company release · Company release
Related companies
Sources
- Public recordFDA 510(k) records K230661, K233903, K242351, K251927, K253663 and K261471
- IndependentMixed reality navigation gets FDA special 510(k) clearance
- InvestorBuilding the robotic surgery platform
- Public recordClinicalTrials.gov NCT07227103, sponsor NeuroRx, Inc.
- Public recordForm D filings, CIK 0001812531
- IndependentZeta Surgical comes out of stealth with a $5.2M raise
- IndependentZeta Surgical zeroes in on FDA nod for ‘GPS-like’ navigation
- IndependentZeta Surgical wins FDA clearance for TMS navigation system
- IndependentFDA clears Zeta Surgical’s robotic TMS navigation system
- InterviewFund Your Way, episode 6
- InterviewZeta Surgical success story
- CompanyFirst patient treated at Singapore’s NNI
- CompanyFirst commercial deployment at HOPE Therapeutics
- CompanyZeta Surgical website and newsroom
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
